RESUMO
Multiple myeloma (MM) accounts for 13％of hematological malignancies, which often happens in elderly patients. The introduction of new drugs and treatments has improved the patients'survival time significantly, but some patients may relapse at different stages of treatment. Some studies have demonstrated that lenalidomide, bortezomib or bortezomib combination regimen could improve progression-free survival (PFS) in the patients at standard risk or at high risk. In patients who are not suitable for transplantation, patients treated with lenalidomide plus dexamethasone regimen consistently have longer survival time than those treated with fixed-cycle melphalan plus prednisone, thalidomide regimen, so the optimal treatment is the appropriate choice. This article reviews the efficacy of fixed-cycle therapy and continuous therapy for post-transplant and non-transplant patients.